newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis

  • IGC Pharma added the Icahn School of Medicine at Mount Sinai as a clinical site for its Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease.
  • Approximately 80% of target participants in the CALMA trial have completed participation, supporting progress toward database lock & topline analysis.
  • The Mount Sinai study is led by Dr. Rachel Fremont, MD, PhD, with local coordination by Katherine Keller.
  • CEO Ram Mukunda stated that adding Mount Sinai reflects a focus on disciplined execution, site quality, & data integrity as the trial nears completion.
  • The inclusion of Mount Sinai expands IGC Pharma's presence in a major metropolitan research center to enhance access to a diverse patient population.
  • IGC-AD1 is currently being evaluated in a randomized, double-blind, placebo-controlled Phase 2 trial designed to assess safety & efficacy for agitation in Alzheimer's disease.
  • IGC Pharma leverages AI to develop treatments for Alzheimer's & metabolic disorders, with a pipeline including IGC-AD1, TGR-63, & early-stage programs targeting neurodegeneration.